alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.4 Promissory Note-Moore


PROMISSORY NOTE







$175,000.00 US Currency         June 19, 2014







FOR VALUE RECEIVED, Invent Ventures, Inc., a Nevada corporation (hereinafter referred to as the "Maker") promises to pay to the order of Aaron Moore, ("Holder"), or assigns, at such other place as the Holder may from time to time designate in writing to the Maker, in lawful money of the United States of America, the principal sum of $175,000.00, or so much thereof as may be hereafter disbursed, without interest.  




SECTION ONE - TERMS




The principal and interest due under this Note shall be paid in the following manner: 




a)  The entire principal amount of this Note, including accrued interest shall be due and payable on or before June 30th, 2015.   




SECTION TWO - RISKS




IN MAKING A DECISION TO LEND FUNDS SUBSCRIBER MUST RELY ON HIS OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE NOTE INSTRUMENT, INCLUDING THE MERITS AND RISKS INVOLVED. A LOAN IN A NEW COMPANY IS CONSIDERED TO BE A HIGH RISK.




The Holder has such knowledge and experience in financial and business matters that the Holder is capable of evaluating the merits and risks of this Promissory Note and of making an informed financial decision, and does not require a Company representative in evaluating the merits and risks, or has relied upon the advice of a Company representative.




The Holder has been given the opportunity to ask question of and to receive answers from persons acting on the Company’s behalf concerning the terms and conditions of this transaction and also has been given the opportunity to obtain any additional information which the Company possesses or can acquire without unreasonable effort or expense. As a result, Holder is cognizant of the financial condition, capitalization, use of proceeds from this financing and the operations and financial condition of Company, has available full information concerning their affairs and has been able to evaluate the merits and risks of the Promissory Note. 




SECTION THREE – OTHER TERMS




Maker hereby waives and renounces for itself, its heirs, successors and assigns, all rights to the benefits of any statute of limitations, any moratorium, reinstatement, marshaling, forbearance, valuation, stay, extension, redemption, appraisement and exemption now provided, or which may hereafter by provided, by the Constitution and laws of the United States of America and of any state thereof, against the enforcement and collection of the obligations evidenced by this Note.




This Note may not be assigned by either party hereto without the prior written consent of the other.  In the event that this Note is collected by law or through an attorney at law, or under advice therefrom, the Maker agrees to pay all costs of collection, including reasonable attorneys' fees.




This Note shall be governed by the laws of the State of Nevada, United States of America. 




Given under the hand and seal of the undersigned, the date and year indicated above.










INVENT VENTURES:

HOLDER:







____________________________

____________________________

Bryce Knight

Aaron Moore

CEO of Invent
Stress management

Stress is what you feel when you have to handle more than you are used to. When you are stressed, 

your body responds as though you are in danger. It makes hormones that speed up your heart, make 

you breathe faster and give you a burst of energy. This is called the fight-or-flight stress response.

Some stress is normal and even useful. The right level of stress can help if you need to work hard or react quickly. For 

example, it can help you win a race or finish a job on time. Too little stress leads to performance below your potential and 

too much impairs performance. The right level of stress for maximum performance is different for each of us.

If stress happens too often, lasts too long or is too high it can have bad effects. It can be linked to headaches, an upset 

stomach, back pain and trouble sleeping. If you already have a health problem, stress may make it worse. It can make you 

moody, tense or depressed. Your relationships may suffer, and you may not do well at work or school.

Tips to cope with stress

Stress is a fact of life for most people. You may not be able to get rid of stress, but you can look for ways to lower it. 

• Manage your time. Make a schedule, think about 

which things are most important and do those first.

• Find better ways to cope. Look at how you have 

been dealing with stress. Be honest about what 

works and what does not. 

• Take good care of yourself. Exercise regularly. Get 

plenty of rest. Eat well. Don’t smoke. Limit how much 

alcohol you drink.

• Reevaluate your thinking. Write down your worries 

and work on letting go of things you cannot change. 

• Focus on the present. Try meditation or guided 

imagery exercises. 

• Let your feelings out. Talk, laugh, cry and express 

anger when you need to.

• Do something you enjoy. A hobby can help you 

relax. Volunteer work or work that helps others can 

be a great stress reliever.

• Ask for help. Building a strong network of friends, 

supporters and family can be a positive tool in 

managing stress.

Sometimes stress is just too much to handle alone. Talking to a friend or family member may help, but you may also want 

to speak to a professional.

B-F2112Erev1 (4/23) ©2023 Magellan Health, Inc.

Help is available. Contact your Employee Assistance Program at 1-866-580-9046 (TTY 711) or visit

MagellanAscend.com for helpful resources.
No. 10-10907.

#### Howard Welsh, Petitioner v. United States.

565 U.S. 932, 132 S. Ct. 375,

181 L. Ed. 2d 237,

2011 U.S. LEXIS 6388.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Justice Kagan took no part in the consideration or decision of this petition.

Same case below, 424 Fed. Appx. 214.
[Federal Register Volume 63, Number 139 (Tuesday, July 21, 1998)]
[Notices]
[Page 39083]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-19367]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission
[Docket No. ER98-3602-000]


Central Hudson Gas & Electric Corporation; Notice of Filing

July 8, 1998.
    Take notice that on July 2, 1998, Central Hudson Gas & Electric 
Corporation (Central Hudson), tendered for filing proposed amendments 
to the Form of Service Agreement For Retail Access of its Open Access 
Transmission Tariff on file in Docket No. OA96-14-000 to implement 
retail access to its system as required by orders of the New York 
Public Service Commission. The details of the proposed amendments are 
more fully described in Central Hudson's filing.
    Any person desiring to be heard or to protest said filing should 
file a motion to intervene or protest with the Federal Energy 
Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in 
accordance with Rules 211 and 214 of the Commission's Rules of Practice 
and Procedure (18 CFR 385.211 and 18 (CFR 385.214). All such motions 
and protests should be filed on or before July 22, 1998. Protests will 
be considered by the Commission to determine the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceedings. Any person wishing to become a party must file a motion to 
intervene. Copies of this filing are on file with the Commission and 
are available for public inspection.
David P. Boergers,
Acting Secretary.
[FR Doc. 98-19367 Filed 7-20-98; 8:45 am]
BILLING CODE 6717-01-M
05/03/2023 CS321570-F 1

Moderna COVID-19 Vaccine

Storage and Handling Summary

BIVALENT

Ages: 6 months through 5 years based on 

immunization history

(pink capped vial with yellow-bordered label)

 BIVALENT 

Ages: 6 months and older based on 

immunization history

(blue capped vial with gray-bordered label)

General Information 

Refer to CDC’s Vaccine Storage and Handling Toolkit for best practices for vaccine storage and handling

1. Use purpose-built or pharmaceutical-grade units designed 

to either refrigerate or freeze.

2. Every vaccine storage unit must have a digital data logger 

temperature monitoring device. 

3. Ensure vaccine is stored at the appropriate temperature. 

4. Monitor and record storage unit temperatures following one 

of these options. Save storage unit records for 3 years, unless 

your jurisdiction requires a longer time period. 

Option 1 (preferred)

Most digital data loggers display the minimum/maximum 

(min/max) temperature. Check and record the min/max 

temperature at the start of each workday.

Option 2

If the digital data logger does not display the min/max 

temperature, check and record the temperature at the 

start and end of each workday.

Delivery 

Vaccine will arrive frozen from the manufacturer between -50°C and -15°C (-58°F and 5°F). Unpack, following the manufacturer’s 

guidance, immediately. The vaccine may be stored in a freezer or refrigerator. Guidance follows. 

Storing UNPUNCTURED Vials 

Freezer

Vaccine may be stored between -50°C and -15°C (-58°F and 5°F) until the expiration date. 

 Store vials upright in the tray or box protected from light

 Do not store with dry ice or below -50°C (-58°F)

 Determine the expiration date by scanning the QR code on the outer carton or go to modernacovid19global.com/vial-lookup

Refrigerator 

Vaccine may be stored between 2°C and 8°C (36°F and 46°F) for 

up to 30 days.

 Do NOT refreeze thawed vaccine

 Store vials upright in the tray or box, protected from light 

 Use tracking labels to monitor the 30-day beyond-use date

Cool/Room Temperature

Vaccine may be stored between 8°C to 25°C (46°F to 77°F) for a 

total of 24 hours.

 Do NOT refreeze thawed vaccine

 Store vials upright in the tray or box, protected from light 

 Track this 24-hour beyond-use time 

Storing PUNCTURED vials 

Store vaccine between 2°C and 25°C (36°F and 77°F) for up to: 

 8 hours—Bivalent vaccine for ages 6 months through 5 years 

(pink capped vial with yellow-bordered label) 

 12 hours—All other Moderna COVID-19 products

 Discard vial and any remaining vaccine after 12 hours 

(8 hours for Bivalent Pink capped yellow-bordered vial) 

 Thawed vials can be handled in room light conditions

 Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 

24 hours
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Company's unaudited financial statements as of May 31, 1999 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          FEB-28-2000
<PERIOD-START>                             MAR-01-1999
<PERIOD-END>                               MAY-31-1999
<CASH>                                          13,453
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     12,790
<CURRENT-ASSETS>                                26,243
<PP&E>                                           7,615
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  33,858
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        12,841
<OTHER-SE>                                      21,017
<TOTAL-LIABILITY-AND-EQUITY>                    33,858
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 2,879
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (2,879)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  1,480
<CHANGES>                                            0
<NET-INCOME>                                   (1,399)
<EPS-BASIC>                                     (0.01)
<EPS-DILUTED>                                   (0.01)


</TABLE>
No. 11-5493.

#### Roger Larry McCluer, Petitioner v. Texas.

565 U.S. 910, 132 S. Ct. 319,

181 L. Ed. 2d 197,

2011 U.S. LEXIS 6093,

October 3, 2011.

Petition for writ of certiorari to the Court of Appeals of Texas, Fourteenth District, denied.
PDF (DLA)

PRODUCT QUALITY DEFICIENCY INVESTIGATION REPORT

3. TO: (Type full address within brackets below) 6. NSN

1. INVESTIGATOR'S CONTROL NUMBER

9. NAME AND ADDRESS OF COMPLAINT INITIATOR 10. NAME AND ADDRESS OF CONTRACTOR

8. NOMENCLATURE

11. REFERENCES AND DESCRIPTION OF DEFICIENCY

12. CAUSE OF DEFICIENCY

13. CORRECTIVE ACTION (BY CONTRACTOR) 

4. ORIGINATOR'S CONTROL NUMBER

7. MANUFACTURER'S PART NUMBER

5. CONTRACT NUMBER

(FORM CONTINUES ON REVERSE SIDE)

2. FROM:

DLA FORM 1227, DEC 88 (EG) PREVIOUS EDITIONS ARE OBSOLETE.
14. CORRECTIVE ACTION (By Government)

19. TYPE OF REPLY 19A. REPLY DATE

21. RECEIVED BY

DLA FORM 1227, DEC 88 (BACK) (EG) PREVIOUS EDITIONS ARE OBSOLETE.

22. APPROVED BY

18. ENCLOSURES TO THIS REPORT AND DISTRIBUTION OF COPIES

20. PREPARED BY

15. EVALUATION OF CURRENT PRODUCTION

16. CONTRACTOR'S POSITION WITH RESPECT TO REPAIR OR REPLACEMENT

17. REMARKS AND/OR RECOMMENDATIONS

INTERIM FINAL
No. 11-5938.

#### Erwin Bernard Redding, Petitioner v. United States.

565 U.S. 925, 132 S. Ct. 358,

181 L. Ed. 2d 226,

2011 U.S. LEXIS 7079.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 422 Fed. Appx. 192.
<PAGE>

                                                                    EXHIBIT 99.1


                  CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND
     CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
           PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the quarterly report on Form 10-QSB of Kanakaris
Wireless (the "Company") for the quarterly period ended December 31, 2002 (the
"Report"), the undersigned hereby certifies in his capacity as Chief Executive
Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         1. the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

         2. the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


         Dated: February 19, 2003            By: /S/ ALEX F. KANAKARIS
                                                 ------------------------------
                                                 Alex F. Kanakaris
                                                 Chief Executive Officer

         In connection with the quarterly report on Form 10-QSB of Kanakaris
Wireless (the "Company") for the quarterly period ended December 31, 2002 (the
"Report"), the undersigned hereby certifies in his capacity as Chief Financial
Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         1. the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.


         Dated: February 19, 2003            By: /S/ DAVID THOMAS SHOMAKER
                                                 ------------------------------
                                                 David Thomas Shomaker
                                                 Acting Chief Financial Officer
#### Ernest C. JOHNSON, Appellant, v. Dr. John P. SHOVLIN, Superintendent of Farview State Hospital, Waymart, Pa.

No. 14705.

United States Court of Appeals Third Circuit.

Submitted March 12, 1964.

Decided April 13, 1964.

Mr. Ernest C. Johnson, pro se.

Walter A. Alessandroni, Atty. Gen., Harrisburg, for appellee.

Before BIGGS, Chief Judge, and HASTIE and SMITH, Circuit Judges.

PER CURIAM.

The appeal of the petitioner appellant from the decision of the court below denying him a writ of habeas corpus is without merit. Consequently, the order appealed from will be affirmed.
*DoD 4000.25-2-M, September 2005*

*Change 4*

*DLM 4000.25, Volume 2, November 26, 2019*

*Change 13*

**AP3.61. APPENDIX 3.61**

**TRANSACTION HISTORY TRANSMITTAL[footnoteRef:1]** [1:  May be used intra-Component or inter-Component when agreed to by the Components involved.] 

## 

2

**AP3.65-**

AP3.61-1

APPENDIX 3.61
No. 11-6237.

#### Elliott Brown, Petitioner v. United States.

565 U.S. 957, 132 S. Ct. 436,

181 L. Ed. 2d 283,

2011 U.S. LEXIS 7194.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 435 Fed. Appx. 182.
May 11, 2016 

Dear Sir or Madam, 

Olof Ekbergh has been issued an exemption, Regulatory Docket No 

FAA-2015-7256 and exemption numbered 16182 (hereinafter the Exemption) for 

the purpose of aerial photography and videography of boating safety, tourism, 

model aircraft safety and real estate. 

Olof Ekbergh hereby respectfully requests an amendment to the exemption to 

allow two additional type of unmanned aircraft system (UAS) that fully complies 

with' the conditions of t~e Exemption., . 

Olof Ekbergh wishes to additionally operate a DJI Phantom 4, DJI Inspire, DJI 

Inspire 1, DJI Inspire 2 and DJI Phantom 4 under the same terms and conditions 

contained in the Exemption. Sent t,Inder separate cover, is the Flight Operations and 

Procedures Manual (FOPM) for the additional UAS. All operations of the 

additional UAS will be in full compliance with the terms of the Exemption. 

As this is an amendment to an existing exemption asking only for the addition of 

another type of unmanned aerial vehicle, Olof Ekbergh respectfully submits that 

good cause exists so that notice does not need to be published in the Federal 

Register for the requested amendment. 

Please feel free to contact the undersigned should you have any question or 

concerns concerning this request for an amendment to the Exemption. 

Olof Ekbergh 

Westside A V Studios 

POB 457 

484 Upper Westside Road 

North Conway NH 03860-0457 

(603) 383-9283 

Site: www. \VestsideA V.com 

Email: Q!.Q.lli'.~}Vv estsi de AV. com 

I' 

1. ,;_
EXHIBIT 23
CONSENT OF CERTIFIED PUBLIC ACCOUNTANTS


We hereby consent to the use of our report dated January 27, 1999 in this Annual
Report on Form 10-K relating to the Consolidated Financial Statements of F&M
National Corporation and Subsidiaries, appearing under Item 8, Financial
Statements and Supplementary Data, including, without limitation, the
incorporation by reference in the Prospectuses constituting part of the
Registration Statements on Form S-8 (#333-63111) and Form S-8 (#333-63113) of
F&M National Corporation.



                     YOUNT, HYDE & BARBOUR, P.C.



March 22, 1999
Winchester, Virginia
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                                   1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-START>                                 OCT-1-1999
<PERIOD-END>                                   DEC-31-1999
<CASH>                                         42,343
<SECURITIES>                                   14,242
<RECEIVABLES>                                  1,605
<ALLOWANCES>                                   415
<INVENTORY>                                    0
<CURRENT-ASSETS>                               58,965
<PP&E>                                         4,295
<DEPRECIATION>                                 794
<TOTAL-ASSETS>                                 80,296
<CURRENT-LIABILITIES>                          11,301
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       29
<OTHER-SE>                                     68,115
<TOTAL-LIABILITY-AND-EQUITY>                   80,296
<SALES>                                        2,383
<TOTAL-REVENUES>                               2,383
<CGS>                                          3,107
<TOTAL-COSTS>                                  3,107
<OTHER-EXPENSES>                               13,798
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             704
<INCOME-PRETAX>                                (13,818)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (13,818)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (13,818)
<EPS-BASIC>                                  (0.51)
<EPS-DILUTED>                                  (0.51)


</TABLE>